Insecticides India Ltd
INSECTICIDInsecticides India Ltd is cheap for a reason. The P/E sits at the 27th percentile of its own range, and the quarters are still getting worse.
The sharpest disagreement: annual EPS moved −1.8% against a −33.2% price move — the market has not yet caught up with the delivery.
The price is in a confirmed uptrend (6 weeks in) while the P/E sits at the 27th percentile of its own 10-year range. Underneath, the last four quarters read deteriorating — profit −14.3% year on year, and 99% of the last 3 years' profit arrived as cash. What settles it: whether the price catches up with earnings that have already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Insecticides India Ltd trades at ₹653, in a confirmed uptrend and 6 weeks into that stage. That is −5.7% against its own 200-day average. It sits at 32% of a 52-week range of ₹556 to ₹859. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (6 weeks and counting).
Today the stock is in a confirmed uptrend — week 6 of stage 2. At ₹653 it trades −5.7% versus its 200-day average and sits at 32% of its 52-week range (₹556–₹859).
Against the market, two honest reads. Cumulative: over the last 10.3 years the stock moved +204% while the NIFTY 500 moved +274% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (6 weeks and counting; last ahead the week of 2026-06-19) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 27th percentile of its own range.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Insecticides India Ltd trades at 12.9× P/E, near the bottom of its own range — cheaper only 27% of the time. Its long-run median P/E is 15.4×, measured across 9.9 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 12.9× is near the bottom of its own range — cheaper only 27% of the time, against a long-run median of 15.4× measured over 9.9 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved −1.8% against a −33.2% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 5y, of the +5.8%/yr price move, ~+7.9%/yr came from earnings growth and ~−2.1 pp from the multiple (compressing); over 10y, of the +7.4%/yr price move, ~+14.0%/yr came from earnings growth and ~−6.6 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.
A quarterly PEG curve, which only the second data source carries, is not drawn on this page: its two data sources do not share enough overlapping reported history to be compared. A figure nobody could check is not used to price growth — the gap is a decision, not missing data.
→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.
Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Insecticides India Ltd reads as mixed on its fundamental arc. Mixed — revenue growth is rising at +18.7% (single-quarter readings) while profit growth is falling at −14.3% (single-quarter readings) — the curves disagree, so the per-curve reads carry the story. The read is built from 10 quarters across 3 curves, on partial evidence.
Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +7.0% | +5.9% | +8.5% | +9.0% |
| Profit | −2.1% | +30.2% | +8.1% | +13.3% |
| EPS | −1.8% | +30.9% | +9.6% | +14.1% |
| Share price | −33.2% | +15.6% | +5.8% | +7.4% |
→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.
4-Factor Sector Score
44.7/100 — rank 17 of 24 in Pesticides/Agrochemicals · 77% evidence confidence
Insecticides India Ltd scores 44.7 out of 100 against the 24 companies it is compared with in Pesticides/Agrochemicals, ranking 17. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 11.9 + 14.1 + 11.6 + 7.1 = 44.7. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Insecticides India Ltd reported ₹426 Cr of revenue in the Mar 26 quarter, +18.7% year on year. That is the 5th straight quarter of year-on-year growth. Over 10 years it has compounded at 9.0% a year. The last full year, FY26, came in at ₹2,140 Cr. The last four reported quarters add to ₹2,140 Cr.
Insecticides India Ltd reported ₹426 Cr of revenue in the Mar 26 quarter, +18.7% year on year. That is the 5th straight quarter of year-on-year growth. Over 10 years it has compounded at 9.0% a year. The last full year, FY26, came in at ₹2,140 Cr. The last four reported quarters add to ₹2,140 Cr.
FY26 revenue came in at ₹2,140 Cr (+7.0% on the year), capping 10 years at 9.0% compound. The latest quarter (Mar 26) printed ₹426 Cr, +18.7% year on year — the 5th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +8.3% growth against the decade's 9.0% — the current year is running in line with its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +6.9% over the last 4 quarters against +4.3%/yr over the last 8 — stabilising; TTM profit −1.4% vs +16.7%/yr — rolling over.
→ Revenue grew — did margins hold as it scaled? Next: 6.0% this quarter (−2.0 pp YoY).
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Insecticides India Ltd's operating margin is 6.0% in the Mar 26 quarter, −2.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 7.0% to 16.0%. The current quarter is running below every full year in that window.
Insecticides India Ltd's operating margin is 6.0% in the Mar 26 quarter, −2.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 7.0% to 16.0%. The current quarter is running below every full year in that window.
The latest quarter's operating margin is 6.0%, −2.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 7.0%–16.0%.
🚨 Why the margin moved: operating margin went −2.0 pp year on year while gross margin went −6.4 pp — the loss came mostly from the gross line: input costs and pricing.
→ Margins slipped — did that reach the bottom line? Next: profit −14.3% in the latest quarter.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Insecticides India Ltd earned ₹12.0 Cr of net profit in the Mar 26 quarter, −14.3% year on year. Full-year FY26 profit was ₹139 Cr. The 10-year compound rate is 13.3%. That is 2.8% of the quarter's revenue. The same quarter a year earlier earned ₹14.0 Cr.
Insecticides India Ltd earned ₹12.0 Cr of net profit in the Mar 26 quarter, −14.3% year on year. Full-year FY26 profit was ₹139 Cr. The 10-year compound rate is 13.3%. That is 2.8% of the quarter's revenue. The same quarter a year earlier earned ₹14.0 Cr.
Mar 26 profit was ₹12.0 Cr, −14.3% year on year. On the full year, FY26 printed ₹139 Cr (−2.1%), and the 10-year compound rate is 13.3%.
🚨 Why profit moved: revenue contributed +18.7% and the margin −2.0 pp — the quarter was revenue-led despite a thinner margin.
Pace comparison, last four quarters: profit −10.1% vs revenue +8.3%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
→ Profit rose — but did the cash follow? Next: 99% of the last 3 years' profit arrived as cash.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 99% of Insecticides India Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹100 Cr of operating cash against ₹139 Cr of profit. After ₹93.0 Cr of capital spending, ₹7.0 Cr was left as free cash.
FY26: operating cash of ₹100 Cr against reported profit of ₹139 Cr, leaving free cash of ₹7.0 Cr after ₹93.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 99% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 99%: the cash cycle held roughly steady between FY21 and FY26 — so conversion tracks profitability rather than the cycle.
Router verdict: the bigger cash user is investment — capital spending ran 2.2× depreciation over three years, so the next section's job is to check what that build-out is buying.
→ So follow the cash to where it goes. Next: ₹208 Cr of building over 3 years.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Insecticides India Ltd's cash conversion cycle runs 177 days in FY26, down from 177 days in FY21. Capital spending ran ₹208 Cr over the last 3 years. At FY26 sales of ₹2,140 Cr each day of that cycle holds about ₹5.9 Cr, so roughly ₹1,038 Cr sits inside the business at any moment.
FY26: debtors at 83 days, inventory at 215 days — roughly 7.1 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 177 days, tighter than FY21's 177.
The full loop: cash goes out to suppliers and production on day 0; stock waits 215 days to sell; customers pay about 83 days after that; and suppliers themselves are paid at 121 days — netting out to the 177-day cycle.
In money terms: at FY26 sales of ₹2,140 Cr, each day of the cycle holds about ₹5.9 Cr — so the 177-day loop keeps roughly ₹1,038 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹208 Cr over the last 3 fiscal years against ₹94.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹130 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
→ Does all this activity actually earn its cost of capital? Next: ROCE is 16% and the ROIC − WACC spread is −0.3 pp.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.⚠ unverified
Insecticides India Ltd earns a ROCE of 16% in FY26. That is up from a trough of 10% in FY23. Return on invested capital clears the cost of that capital by −0.3 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 6.5% net margin on 1.07× asset turns.
FY26 ROCE is 16%, recovered from a FY23 trough of 10% — the full ladder below shows the fall and the climb, undoctored.
🚨 Why the return is what it is — the wiring (FY26): 6.5% net margin × 1.07× asset turns × 1.64× balance-sheet leverage ≈ 11.4% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 11.7% − 12.0% = a −0.3 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.13.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.⚠ unverified
Insecticides India Ltd carries total debt of ₹157 Cr against shareholder equity of ₹1,220 Cr as of Mar 26, a debt-to-equity of 0.13 — effectively unlevered. On the annual view that ratio went from 0.06 in FY22 to 0.13 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of ₹157 Cr against shareholder equity of ₹1,220 Cr — a debt-to-equity of 0.13. On the annual view, debt-to-equity went from 0.06 (FY22) to 0.13 (FY26). The returns on this page are earned, not borrowed.
→ Who owns this, and are they adding or leaving? Next: the register is quiet.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
No holder of Insecticides India Ltd moved a full percentage point over the last two years — the register is quiet. Promoters moved +0.1 points over the same window, to 72.3%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Domestic institutions: +0.2 points over 8 quarters to 9.3%; Promoters: +0.1 points over 8 quarters to 72.3%; Foreign institutions: +0.0 points over 8 quarters to 4.4%.
→ One last check: does the safety math agree? Next: the balance-sheet safety line.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Insecticides India Ltd: the Z-score reads 4.36. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 4.36 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 4.36.
| Company | P/E | Mkt cap | Revenue | EPS | ROCE | Stage |
|---|---|---|---|---|---|---|
| Insecticides India Ltd this page | 12.9× | ₹1,793 Cr | Mixed | |||
| UPL Ltd | 28.2× | ₹50,841 Cr | No read | |||
| P I Industries Ltd | 34.5× | ₹41,437 Cr | Deteriorating | |||
| Sumitomo Chemical India Ltd | 50.9× | ₹25,978 Cr | Mixed | |||
| Bayer CropScience Ltd | 385.0× | ₹18,954 Cr | — | — | — | — |
| Jubilant Ingrevia Ltd | 36.3× | ₹11,557 Cr | Mixed | |||
| Sharda Cropchem Ltd | 12.1× | ₹7,876 Cr | Mixed | |||
| Epigral Ltd | 15.2× | ₹5,016 Cr | Mixed | |||
| NACL Industries Ltd | 178.0× | ₹4,610 Cr | No read | |||
| Dhanuka Agritech Ltd | 15.5× | ₹4,517 Cr | Topping out | |||
| Rallis India Ltd | 26.9× | ₹4,253 Cr | Mixed | |||
| Bhagiradha Chemicals & Industries Ltd | 188.0× | ₹3,416 Cr | Improving | |||
| GSP Crop Science Ltd | 24.4× | ₹2,468 Cr | — | — | — | — |
| Bharat Rasayan Ltd | 13.1× | ₹2,096 Cr | Mixed | |||
| India Pesticides Ltd | 14.4× | ₹1,727 Cr | Mixed | |||
| Titan Biotech Ltd | 57.5× | ₹1,719 Cr | Turning around | |||
| Astec Lifesciences Ltd | — | ₹1,469 Cr | No read | |||
| Meghmani Organics Ltd | 48.2× | ₹1,385 Cr | No read | |||
| Punjab Chemicals & Crop Protection Ltd | 21.0× | ₹1,375 Cr | Mixed | |||
| Excel Industries Ltd | 15.5× | ₹1,172 Cr | Mixed | |||
| Titan Biotech Ltd | 42.0× | ₹1,141 Cr | Turning around | |||
| Dharmaj Crop Guard Ltd | 16.1× | ₹882 Cr | No read | |||
| Advance Agrolife Ltd | 20.0× | ₹706 Cr | No read | |||
| Heranba Industries Ltd | — | ₹700 Cr | No read | |||
| Best Agrolife Ltd | 60.6× | ₹538 Cr | No read |
Frequently asked questions
What is Insecticides India Ltd's share price today?
Insecticides India Ltd trades at ₹653, −33.2% over the past year. The company is valued at ₹1,793 Cr. The stock sits at 32% of its 52-week range of ₹556–₹859, −5.7% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 6 weeks in. — as of 24 July 2026.
What were Insecticides India Ltd's latest quarterly results?
Insecticides India Ltd reported revenue of ₹426 Cr and net profit of ₹12.0 Cr for the Mar 26 quarter. Revenue rose 18.7% and profit fell 14.3% year on year. Earnings per share were ₹4.02. The operating margin was 6.0%, 2.0 pp lower than a year earlier. — as of 24 July 2026.
What is Insecticides India Ltd's revenue?
Insecticides India Ltd reported revenue of ₹426 Cr in the Mar 26 quarter, +18.7% year on year. For the full FY26 fiscal year, revenue was ₹2,140 Cr (+7.0%). Over the last 10 years revenue compounded at 9.0% a year. — as of 24 July 2026.
What is Insecticides India Ltd's profit?
Insecticides India Ltd earned ₹12.0 Cr of net profit in the Mar 26 quarter, −14.3% year on year. Full-year FY26 profit was ₹139 Cr. The operating margin ran 6.0% in the latest quarter. — as of 24 July 2026.
What is Insecticides India Ltd's market cap?
Insecticides India Ltd's market capitalisation is ₹1,793 Cr at a share price of ₹653. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 24 July 2026.
What is Insecticides India Ltd's P/E ratio?
Insecticides India Ltd trades at a P/E of 12.9×, at the 27th percentile of its own 10-year range, against a long-run median of 15.4×. This is a comparison with the stock's own history, not a value call — as of 24 July 2026.
Does Insecticides India Ltd pay a dividend?
Yes — Insecticides India Ltd's dividend payout was 4% of profit in FY26, and it recorded a payout in 12 of its last 13 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 24 July 2026.
Is Insecticides India Ltd overvalued?
On its own history, Insecticides India Ltd looks cheap against its own history: its P/E of 12.9× has been cheaper only 27% of the time in 10 years (long-run median 15.4×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 24 July 2026.
Is Insecticides India Ltd growing?
Not right now — Insecticides India Ltd's latest numbers are shrinking: latest-quarter revenue +18.7% year on year, profit −14.3%, and the margin −2.0 pp at 6.0%. The 10-year compound rates are 9.0% (revenue) and 13.3% (profit). The earnings engine currently reads: deteriorating — as of 24 July 2026.
How is Insecticides India Ltd performing?
Insecticides India Ltd is in a confirmed uptrend, 6 weeks in. Its latest quarter's revenue rose 18.7% and profit fell 14.3% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 6 weeks. This describes what the data did, not a rating. — as of 24 July 2026.
What stage is Insecticides India Ltd in?
Mixed — revenue growth is rising at +18.7% (single-quarter readings) while profit growth is falling at −14.3% (single-quarter readings) — the curves disagree, so the per-curve reads carry the story. The read comes from the last 12 quarters of growth (revenue growth +18.7% latest, profit growth −14.3% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 24 July 2026.
Is Insecticides India Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 6 of stage 2), trading −5.7% versus its 200-day average and at 32% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 24 July 2026.
Is Insecticides India Ltd beating the market?
Not lately — on a trailing-13-week view Insecticides India Ltd is currently behind the NIFTY 500 (6 weeks and counting; last ahead the week of 2026-06-19), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.3 years the stock moved +204% against the NIFTY 500's +274% — behind the index over the full window. — as of 24 July 2026.
Will Insecticides India Ltd's share price go up?
This page publishes no price forecast for Insecticides India Ltd. What it measures instead: the share price is ₹653, the price is in a confirmed uptrend 6 weeks in. Its P/E of 12.9× sits at the 27th percentile of its own 10-year range. — as of 24 July 2026.
Who owns Insecticides India Ltd?
Promoters hold 72.3% of Insecticides India Ltd, foreign institutions 4.4%, domestic institutions 9.3% and the public 14.0% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 24 July 2026.
Does Insecticides India Ltd have too much debt?
No — Insecticides India Ltd's debt-to-equity is 0.13, and operating profit covers the interest bill 13×. FY26 borrowings were ₹157 Cr against equity of ₹1,220 Cr. The returns on this page are earned, not borrowed — as of 24 July 2026.
What is Insecticides India Ltd's capex?
Insecticides India Ltd spent ₹208 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹93.0 Cr, with ₹130 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 24 July 2026.
What is Insecticides India Ltd's cash flow?
Insecticides India Ltd generated ₹100 Cr of operating cash flow in FY26 and ₹7.0 Cr of free cash flow after ₹93.0 Cr of capital spending. Reported profit that year was ₹139 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 24 July 2026.
Is Insecticides India Ltd's profit real cash?
Yes — over the last 3 fiscal years, 99% of Insecticides India Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹100 Cr against reported profit of ₹139 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 24 July 2026.
How financially safe is Insecticides India Ltd?
On the balance sheet, the Z-score reads 4.36 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 24 July 2026.
Where is Insecticides India Ltd in its business cycle?
Insecticides India Ltd's FY26 operating margin was 11.0%, against a 13-year band of 7.0%–16.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 6.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 24 July 2026.
What could break the Insecticides India Ltd story?
The sharpest disagreement: annual EPS moved −1.8% against a −33.2% price move — the market has not yet caught up with the delivery. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 24 July 2026.
Is Insecticides India Ltd a stock worth studying right now?
This is not investment advice. The machine read: Insecticides India Ltd is cheap for a reason. The P/E sits at the 27th percentile of its own range, and the quarters are still getting worse. The sharpest open question: whether the price catches up with earnings that have already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 24 July 2026.